Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains a Neutral rating on ImmunityBio (NASDAQ:IBRX) and raises the price target from $5 to $6.
April 29, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on ImmunityBio and raises the price target from $5 to $6.
The increase in price target by Piper Sandler suggests a positive outlook on ImmunityBio's stock value in the short term, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90